Strategic Diagnostics Inc. (SDIX, Financial) filed Quarterly Report for the period ended 2010-06-30.
Strategic Diagnostics Inc. has a market cap of $33.5 million; its shares were traded at around $1.646 with and P/S ratio of 1.3. SDIX is in the portfolios of Chuck Royce of Royce& Associates, Jim Simons of Renaissance Technologies LLC.
Kit product revenues decreased 13% to $3.0 million for the three months ended June 30, 2010 compared to $3.5 million in the same period of 2009. Sales of food pathogen products decreased 7% to $1.3 million; Ag-GMO product sales decreased 17%, to $0.5 million and water and environmental products revenue decreased 17%, to $1.2 million in the three month period ended June 30, 2010 as compared to the same period of 2009.
Net loss was $215,000, or $0.01 per diluted share, in the three month period ended June 30, 2010, compared to a net loss of $734,000, or $0.04 per diluted share, for the same period in 2009. Diluted shares utilized in these computations were 20.2 million and 20.1 million for the 2010 and 2009 periods, respectively.
Life Science revenues increased 6% to $7.5 million for the six month period ended June 30, 2010, compared to $7.0 million for the same period in 2009. Sales of custom monoclonal products increased 51% to $2.1 million; custom polyclonal product sales increased 8% to $3.1 million. These increases were partially offset by a decrease in sales of products utilizing the GAT TM platform of 30% to $0.6 million and a decrease in sales of bulk antibody products of 11% to $1.7 million. This increase in Life Science revenues was primarily the result of increased sales to the Company s customers in the biopharma and antibody catalog industries.
Kit product revenues decreased 10% to $6.0 million for the six months ended June 30, 2010 compared to $6.6 million in the same period of 2009. Sales of food pathogen products decreased 3% to $2.7 million; Ag-GMO product sales decreased 11%, to $1.1 million and water and environmental products revenue decreased 17%, to $2.2 million in the six month period ended June 30, 2010 as compared to the same period of 2009.
Net loss was $674,000, or $0.03 per diluted share, in the six month period ended June 30, 2010, compared to a net loss of $1.3 million, or $0.06 per diluted share, for the same period in 2009. Diluted shares utilized in these computations were 20.2 million and 20.1 million for the 2010 and 2009 periods, respectively.
Read the The complete Report
Strategic Diagnostics Inc. has a market cap of $33.5 million; its shares were traded at around $1.646 with and P/S ratio of 1.3. SDIX is in the portfolios of Chuck Royce of Royce& Associates, Jim Simons of Renaissance Technologies LLC.
Highlight of Business Operations:
Life Science revenues increased 10% to $3.7 million for the three month period ended June 30, 2010, compared to $3.3 million for the same period in 2009. Sales of custom monoclonal products increased 41% to $1.0 million; custom polyclonal product sales increased 9% to $1.6 million and sales of bulk antibody products increased 5% to $0.8 million. These increases were partially offset by a decrease in sales of products utilizing the GAT TM platform of 29% to $0.3 million. This increase in Life Science revenues was primarily the result of increased sales to the Company s customers in the biopharma and antibody catalog industries.Kit product revenues decreased 13% to $3.0 million for the three months ended June 30, 2010 compared to $3.5 million in the same period of 2009. Sales of food pathogen products decreased 7% to $1.3 million; Ag-GMO product sales decreased 17%, to $0.5 million and water and environmental products revenue decreased 17%, to $1.2 million in the three month period ended June 30, 2010 as compared to the same period of 2009.
Net loss was $215,000, or $0.01 per diluted share, in the three month period ended June 30, 2010, compared to a net loss of $734,000, or $0.04 per diluted share, for the same period in 2009. Diluted shares utilized in these computations were 20.2 million and 20.1 million for the 2010 and 2009 periods, respectively.
Life Science revenues increased 6% to $7.5 million for the six month period ended June 30, 2010, compared to $7.0 million for the same period in 2009. Sales of custom monoclonal products increased 51% to $2.1 million; custom polyclonal product sales increased 8% to $3.1 million. These increases were partially offset by a decrease in sales of products utilizing the GAT TM platform of 30% to $0.6 million and a decrease in sales of bulk antibody products of 11% to $1.7 million. This increase in Life Science revenues was primarily the result of increased sales to the Company s customers in the biopharma and antibody catalog industries.
Kit product revenues decreased 10% to $6.0 million for the six months ended June 30, 2010 compared to $6.6 million in the same period of 2009. Sales of food pathogen products decreased 3% to $2.7 million; Ag-GMO product sales decreased 11%, to $1.1 million and water and environmental products revenue decreased 17%, to $2.2 million in the six month period ended June 30, 2010 as compared to the same period of 2009.
Net loss was $674,000, or $0.03 per diluted share, in the six month period ended June 30, 2010, compared to a net loss of $1.3 million, or $0.06 per diluted share, for the same period in 2009. Diluted shares utilized in these computations were 20.2 million and 20.1 million for the 2010 and 2009 periods, respectively.
Read the The complete Report
